FDA Approved: BRAFTOVI — Supplemental Application (Array BioPharma Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BRAFTOVI (encorafenib) submitted by Array BioPharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)

Snippet

SUPPL AP for BRAFTOVI (ENCORAFENIB)